Evolus Days Payables Outstanding vs Price To Sales Ratio Analysis

EOLS Stock

USD 13.80 0.97 7.56%

Evolus financial indicator trend analysis is much more than just examining Evolus Inc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evolus Inc is a good investment. Please check the relationship between Evolus Days Payables Outstanding and its Price To Sales Ratio accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Days Payables Outstanding vs Price To Sales Ratio

Days Payables Outstanding vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evolus Inc Days Payables Outstanding account and Price To Sales Ratio. At this time, the significance of the direction appears to have very week relationship.

The correlation between Evolus' Days Payables Outstanding and Price To Sales Ratio is 0.2. Overlapping area represents the amount of variation of Days Payables Outstanding that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Evolus Inc, assuming nothing else is changed. The correlation between historical values of Evolus' Days Payables Outstanding and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Payables Outstanding of Evolus Inc are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Days Payables Outstanding i.e., Evolus' Days Payables Outstanding and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.2

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Days Payables Outstanding

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Evolus Inc stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Evolus sales, a figure that is much harder to manipulate than other Evolus Inc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Evolus' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evolus Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Evolus' Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.91 in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

Evolus fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Non Currrent Assets Other	Capital Surpluse
Total Assets		0.46	0.69	0.14	-0.77	0.74	0.3	-0.36	-0.76	0.78	0.93	0.19	-0.27	0.73	0.61	0.88	0.65	0.57	0.77	-0.93	0.55	1.0	-0.28	-0.39	-0.92	0.85
Short Long Term Debt Total	0.46		0.4	0.83	-0.3	0.0	-0.6	0.64	-0.38	0.34	0.16	0.1	-0.25	0.34	0.25	0.27	0.15	0.24	0.85	-0.56	0.86	0.45	0.61	-0.22	-0.59	0.48
Other Current Liab	0.69	0.4		0.4	-0.74	0.5	-0.18	-0.24	-0.71	0.87	0.7	0.09	-0.16	0.62	0.4	0.64	0.8	0.67	0.78	-0.62	0.22	0.69	-0.16	-0.36	-0.61	0.59
Total Current Liabilities	0.14	0.83	0.4		-0.31	-0.2	-0.85	0.67	-0.05	0.18	-0.07	0.1	0.06	0.0	-0.13	-0.14	0.08	0.02	0.67	-0.24	0.65	0.14	0.83	0.05	-0.27	0.1
Total Stockholder Equity	-0.77	-0.3	-0.74	-0.31		-0.55	-0.13	0.43	0.36	-0.6	-0.83	-0.4	-0.15	-0.34	-0.14	-0.52	-0.74	-0.32	-0.61	0.59	-0.29	-0.77	0.06	-0.04	0.58	-0.44
Other Liab	0.74	0.0	0.5	-0.2	-0.55		0.46	-0.64	-0.51	0.57	0.84	0.12	-0.21	0.44	0.32	0.75	0.33	0.27	0.4	-0.75	0.21	0.74	-0.52	-0.19	-0.73	0.58
Net Tangible Assets	0.3	-0.6	-0.18	-0.85	-0.13	0.46		-0.82	-0.13	0.03	0.48	0.07	-0.01	0.22	0.29	0.39	0.2	0.12	-0.37	-0.15	-0.32	0.3	-0.79	-0.08	-0.11	0.22
Net Debt	-0.36	0.64	-0.24	0.67	0.43	-0.64	-0.82		0.19	-0.31	-0.65	-0.18	-0.16	-0.22	-0.14	-0.44	-0.44	-0.22	0.21	0.18	0.45	-0.37	0.81	-0.01	0.15	-0.19
Retained Earnings	-0.76	-0.38	-0.71	-0.05	0.36	-0.51	-0.13	0.19		-0.81	-0.67	0.29	0.62	-0.94	-0.91	-0.86	-0.65	-0.89	-0.7	0.77	-0.37	-0.76	0.44	0.84	0.76	-0.9
Accounts Payable	0.78	0.34	0.87	0.18	-0.6	0.57	0.03	-0.31	-0.81		0.74	0.13	-0.18	0.75	0.54	0.78	0.64	0.71	0.73	-0.73	0.27	0.78	-0.33	-0.43	-0.71	0.72
Cash	0.93	0.16	0.7	-0.07	-0.83	0.84	0.48	-0.65	-0.67	0.74		0.19	-0.18	0.63	0.5	0.84	0.72	0.53	0.58	-0.81	0.27	0.94	-0.48	-0.3	-0.79	0.72
Non Current Assets Total	0.19	0.1	0.09	0.1	-0.4	0.12	0.07	-0.18	0.29	0.13	0.19		0.76	-0.12	-0.48	0.12	0.05	-0.21	0.1	-0.05	0.01	0.19	0.15	0.73	-0.05	-0.05
Good Will	-0.27	-0.25	-0.16	0.06	-0.15	-0.21	-0.01	-0.16	0.62	-0.18	-0.18	0.76		-0.4	-0.69	-0.38	-0.15	-0.36	-0.3	0.35	-0.25	-0.25	0.29	0.81	0.36	-0.4
Common Stock Shares Outstanding	0.73	0.34	0.62	0.0	-0.34	0.44	0.22	-0.22	-0.94	0.75	0.63	-0.12	-0.4		0.9	0.85	0.63	0.95	0.63	-0.75	0.37	0.75	-0.41	-0.76	-0.73	0.95
Short Term Investments	0.61	0.25	0.4	-0.13	-0.14	0.32	0.29	-0.14	-0.91	0.54	0.5	-0.48	-0.69	0.9		0.71	0.52	0.85	0.46	-0.64	0.35	0.61	-0.45	-0.93	-0.62	0.85
Non Current Liabilities Total	0.88	0.27	0.64	-0.14	-0.52	0.75	0.39	-0.44	-0.86	0.78	0.84	0.12	-0.38	0.85	0.71		0.61	0.72	0.64	-0.83	0.31	0.88	-0.56	-0.52	-0.81	0.88
Other Current Assets	0.65	0.15	0.8	0.08	-0.74	0.33	0.2	-0.44	-0.65	0.64	0.72	0.05	-0.15	0.63	0.52	0.61		0.73	0.51	-0.43	0.0	0.66	-0.38	-0.41	-0.41	0.55
Other Stockholder Equity	0.57	0.24	0.67	0.02	-0.32	0.27	0.12	-0.22	-0.89	0.71	0.53	-0.21	-0.36	0.95	0.85	0.72	0.73		0.55	-0.55	0.18	0.59	-0.4	-0.78	-0.53	0.82
Total Liab	0.77	0.85	0.78	0.67	-0.61	0.4	-0.37	0.21	-0.7	0.73	0.58	0.1	-0.3	0.63	0.46	0.64	0.51	0.55		-0.81	0.74	0.77	0.22	-0.39	-0.82	0.74
Deferred Long Term Liab	-0.93	-0.56	-0.62	-0.24	0.59	-0.75	-0.15	0.18	0.77	-0.73	-0.81	-0.05	0.35	-0.75	-0.64	-0.83	-0.43	-0.55	-0.81		-0.72	-0.93	0.15	0.48	1.0	-0.9
Short Long Term Debt	0.55	0.86	0.22	0.65	-0.29	0.21	-0.32	0.45	-0.37	0.27	0.27	0.01	-0.25	0.37	0.35	0.31	0.0	0.18	0.74	-0.72		0.55	0.52	-0.27	-0.75	0.59
Total Current Assets	1.0	0.45	0.69	0.14	-0.77	0.74	0.3	-0.37	-0.76	0.78	0.94	0.19	-0.25	0.75	0.61	0.88	0.66	0.59	0.77	-0.93	0.55		-0.28	-0.39	-0.92	0.86
Short Term Debt	-0.28	0.61	-0.16	0.83	0.06	-0.52	-0.79	0.81	0.44	-0.33	-0.48	0.15	0.29	-0.41	-0.45	-0.56	-0.38	-0.4	0.22	0.15	0.52	-0.28		0.36	0.11	-0.28
Intangible Assets	-0.39	-0.22	-0.36	0.05	-0.04	-0.19	-0.08	-0.01	0.84	-0.43	-0.3	0.73	0.81	-0.76	-0.93	-0.52	-0.41	-0.78	-0.39	0.48	-0.27	-0.39	0.36		0.47	-0.68
Non Currrent Assets Other	-0.92	-0.59	-0.61	-0.27	0.58	-0.73	-0.11	0.15	0.76	-0.71	-0.79	-0.05	0.36	-0.73	-0.62	-0.81	-0.41	-0.53	-0.82	1.0	-0.75	-0.92	0.11	0.47		-0.89
Capital Surpluse	0.85	0.48	0.59	0.1	-0.44	0.58	0.22	-0.19	-0.9	0.72	0.72	-0.05	-0.4	0.95	0.85	0.88	0.55	0.82	0.74	-0.9	0.59	0.86	-0.28	-0.68	-0.89

Click cells to compare fundamentals

Evolus Account Relationship Matchups

Evolus fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	240.4M	209.1M	257.5M	178.0M	189.0M	190.3M
Short Long Term Debt Total	96.5M	138.3M	74.7M	73.2M	126.5M	103.1M
Other Current Liab	17.4M	95.0M	49.0M	34.9M	30.2M	28.6M
Total Current Liabilities	24.4M	180.2M	57.7M	46.5M	48.3M	61.0M
Total Stockholder Equity	(213.1M)	(376.1M)	(422.9M)	18.5M	(20.7M)	(21.7M)
Other Liab	59.1M	58.1M	44.5M	39.9M	45.9M	46.9M
Net Tangible Assets	(1.4M)	(149.5M)	10.0M	(51.3M)	(59.0M)	(62.0M)
Net Debt	(13.3M)	35.8M	(71.5M)	19.3M	63.7M	66.9M
Retained Earnings	(213.1M)	(376.1M)	(422.9M)	(497.3M)	(559.0M)	(531.0M)
Accounts Payable	5.8M	9.6M	6.1M	8.9M	4.3M	4.9M
Cash	109.9M	102.6M	146.3M	53.9M	62.8M	70.0M
Non Current Assets Total	88.2M	81.5M	78.7M	77.2M	76.6M	63.4M
Common Stock Shares Outstanding	28.2M	33.7M	49.8M	56.1M	56.9M	37.9M
Liabilities And Stockholders Equity	(52.1M)	(94.0M)	(247.3M)	178.0M	189.0M	198.4M
Non Current Liabilities Total	136.5M	101.8M	117.9M	113.0M	161.4M	94.2M
Other Current Assets	5.3M	11.8M	16.1M	5.6M	8.1M	6.4M
Other Stockholder Equity	(7K)	303.1M	504.8M	516.1M	538.7M	272.4M
Total Liab	161.0M	282.0M	175.6M	159.5M	209.7M	178.1M
Total Current Assets	152.2M	127.6M	178.8M	100.8M	112.4M	103.1M
Intangible Assets	59.6M	55.3M	50.6M	48.6M	47.1M	43.2M
Non Currrent Assets Other	2.4M	240K	2.8M	2.8M	409K	388.6K
Other Assets	2.4M	3.7M	32.5M	2.8M	1.0	0.95
Net Invested Capital	170.9M	61M	153.1M	90.4M	99.7M	92.8M
Net Working Capital	127.8M	(52.6M)	121.1M	54.3M	64.1M	41.5M
Long Term Debt	91.5M	40.5M	71.2M	71.9M	120.4M	75.6M
Cash And Short Term Investments	129.8M	107.6M	146.3M	53.9M	62.8M	79.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Evolus Stock Analysis

When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC